Our work establishes the IL-4 mediated cancer cell TAP2 downregulation as a novel, dominant and potentially actionable mechanism of T-cell immune evasion and immunotherapy resistance in human NSCLC and elucidates the mechanism mediating these responses with broad biological and potential clinical implications. The gene discussed is IL4; the disease is cancer.